Abstract:SESSION TITLE: Cough SESSION TYPE: Original Investigation Slide PRESENTED ON: Sunday, April 17, 2016 at 08:30 AM - 09:30 AM PURPOSE: To evaluated the efficacy and safety of oral specific neuromodulators on refractory chronic cough. METHODS: We assessed clinical and preclinical RCTs studies of the neuromodulating agents, baclofen, amitriptyline, gabapentin, deanxit and pregbalin, for the treatment of human cough with no restriction to language. Data were extracted from PubMed, EMBASE, LILACS, CBM, CNKI, VIP, WanFang and Cochrane Controlled Trials Register (CENTRAL) databases. Literature was searched by the two authors with a priori criteria for study selection. The outcome data were number of possible cases whose cough threshold to inhaled capsaicin C5 changed or those cough symptom improved, measured by cough or LCQ score, after treatment. RESULTS: Three relevant articles, about three medicines of baclofen, gabepentin and amitriptyline respectively, were identified, all are randomized controlled trials. 201 persons in total were enrolled in this study all associated with specific oral centrally acting medicines. After treatment of oral centrally acting medicines the elevated effect on C5 or relief of cough symptoms was significant (risk ratio [RR]1.64; 95% CI,0.93-2.89) (Picture 1). They was well tolerated with minimal side effects. Methodological biases in the design and execution of cluster randomized trials might contributed to the selection bias in this review (Picture 2). CONCLUSIONS: We confirm the recent observation that therapy with baclofen or gabepentin or amitriptyline decrease cough reflex sensitivity in human subjects of refractory chronic cough. Different methodological might contributed to a selection bias in our results. CLINICAL IMPLICATIONS: To our knowledge this is the first systematic review and meta-analysis of evaluating RCTs studies of the efficacy and safety of oral specific neuromodulators on refractory chronic cough. We confirm the recent observation that therapy with baclofen or gabepentin or amitriptyline decrease cough reflex sensitivity in human subjects of refractory chronic cough. More work should be done in this area. DISCLOSURE: The following authors have nothing to disclose: Weili Wei, Yangzi ZhangTong, Mei He, Hanjing Lv, Zhongmin Qiu No Product/Research Disclosure Information

SENSORY NEURAL TARGETS FOR THE TREATMENT OF COUGH

Translating Cough Mechanisms Into Better Cough Suppressants

Cough reflex hypersensitivity: A role for neurotrophins

From bench to bedside: The role of cough hypersensitivity in chronic cough

Mechanisms and Rationale for Targeted Therapies in Refractory and Unexplained Chronic Cough

Cough Reflex Hypersensitivity as a Key Treatable Trait

Are neural pathways processing airway inputs sensitized in patients with cough hypersensitivity?

Drugs Targeting Cough Receptors: New Therapeutic Options in Refractory or Unexplained Chronic Cough

Sensorimotor circuitry involved in the higher brain control of coughing

Neural Mechanisms Underlying the Coughing Reflex

Afferent neural pathways mediating cough in animals and humans.

Neural correlates of cough hypersensitivity in humans: evidence for central sensitisation and dysfunctional inhibitory control

The efficacy of specific neuromodulators on human refractory chronic cough: a systematic review and meta-analysis.

Central pathways for cough in man--unanswered questions

Efficacy of Oral Specific Neuromodulators on Human Refractory Chronic Cough: A Systematic Review and Meta-analysis

The Role of ATP in Cough Hypersensitivity Syndrome: New Targets for Treatment

Brainstem processing of cough sensory inputs in chronic cough hypersensitivity

Cough hypersensitivity and chronic cough

Cough: some aspects of pathogenesis and therapeutic approaches

Anatomy and neurophysiology of cough: CHEST Guideline and Expert Panel report

Cough Reflex Sensitivity And Airway Inflammation In Patients With Chronic Cough Due To Non-Acid Gastro-Oesophageal Reflux